ROCHESTER, N.Y., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, reported today its third quarter fiscal 2025 financial results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Chief Financial Officer, Garth Hankinson, on Friday, January 10, 2025 at 10:30 a.m. ET. Visit ir.cbrands.com to locate information for joining the conference call, or a live, listen- ...

VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone solutions driven by Quantum Computing, Drones as a Service, and enterprise SaaS, announces that its subsidiary company ZenaDrone has applied for a Federal Aviation Authority (FAA) Part 137, crop sprayer “Agricultural Aircraft Operations Certification” to use its ZenaDrone 1000 drone for spraying including for agricultura ...

2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming events, including Phase 3 results for pelacarsen Royalty Pharma to benefit from new product launches in 2025, including Servier’s Voranigo, Bristol Myers Squibb’s Cobenfy, Ascendis’ Yorvipath, Syndax and Incyte’s Niktimvo and Geron’s Rytelo NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma ...

Partnership Overview - Absci Corporation and Owkin announced a strategic partnership to combine their AI platforms for the discovery and design of novel therapeutics [1] - The collaboration aims to accelerate the development of first-in-class therapeutics by leveraging Absci's AI de novo design models and Owkin's predictive AI target discovery technology [1][2] - The partnership will focus on co-developing therapeutic candidates in immuno-oncology, immunology, and inflammation [2] Technology and Capabilities - Owkin's predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids [2] - Absci's generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against novel targets [2] - The combined technologies aim to streamline and accelerate the path from research to clinical development [2] Strategic Impact - The partnership builds on Absci's growing portfolio of collaborations with industry leaders such as AstraZeneca and Merck [3] - Absci has added four new drug creation partnerships in 2024, achieving its outlook for the year [3] - Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies like Sanofi and BMS [3] Company Background - Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to accelerate the development of biologics [4] - The company's Integrated Drug Creation™ platform can screen billions of cells per week, enabling the transition from AI-designed antibodies to wet lab-validated candidates in as little as six weeks [4] - Owkin is an end-to-end AI biotech company focused on understanding complex biology and developing precision therapeutics, diagnostics, and de-risking clinical trials [5] - Owkin has raised over $300 million from leading biopharma companies and venture funds [5] Future Directions - The collaboration aims to bring transformative therapies to patients by combining Owkin's AI agents for target identification and validation with Absci's capabilities in developing biologic drug candidates [3] - The partnership represents a significant step forward in leveraging AI to accelerate the delivery of next-generation treatments [3]

LOUISVILLE, Ky., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (“CDI” or “the Company”) announced today that the Company will release fourth quarter and full year 2024 financial results after the market closes on Wednesday, February 19, 2025, and host a related conference call to discuss the quarter on Thursday, February 20, 2025, at 9 a.m. ET. Investors and other interested parties may listen to the call by accessing the online, real-time webcast at http://ir.churchilldownsincorporated.com ...

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, has joined Tourmaline’s Ca ...

HOUSTON, TX, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”) today announced the on-time completion of its initial eight-well Shelduck South pad in the DJ Basin and is set to have production fully online in the first quarter of 2025. The Shelduck pad, together with recent Nickel Road Operating (NRO) acquisition, represents the first phase in Prairie's 2025 development program. “The on-time completion of the Shelduck South pad is a testament to the hard wor ...

Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Herpes Zoster (Shingles) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on nu ...

Product Innovations and M&As Driving the Global Market, Which is Projected to Register 25.1% CAGRDublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Hard Seltzer Market 2024-2028" report has been added to ResearchAndMarkets.com's offering.The hard seltzer market is forecasted to grow by USD 36.43 billion during 2023-2028, accelerating at a CAGR of 25.1% during the forecast period. This report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analys ...

Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Uterine Leiomyoma: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.This reports provides a data-driven overview of the current and future competitive landscape in Uterine Leiomyoma therapeutics.In 2024, more than 16 million incident cases of UL are anticipated in the 16 countries covered in the analyst's epidemiology forecast.Currently, the treatment of UL is dominated by gonadotropin-releasing hormone (GnRH) agonist drugs. R& ...